CGH
VRTX icon

Crossmark Global Holdings’s Vertex Pharmaceuticals VRTX Stock Holding History

Crossmark Global Holdings’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.4M Buy
2,828
+124
+5% +$55K 0.02% 549
2026
Q1 		$1.21M Sell
2,704
-93
-3% -$43.4K 0.02% 557
2025
Q4 		$1.27M Sell
2,797
-3,346
-54% -$1.44M 0.02% 542
2025
Q3 		$2.41M Sell
6,143
-78
-1% -$32.6K 0.04% 394
2025
Q2 		$2.77M Buy
6,221
+47
+0.8% +$21.7K 0.04% 350
2025
Q1 		$2.99M Sell
6,174
-33
-0.5% -$15.4K 0.05% 316
2024
Q4 		$2.5M Buy
6,207
+341
+6% +$158K 0.05% 343
2024
Q3 		$2.73M Sell
5,866
-298
-5% -$143K 0.05% 340
2024
Q2 		$2.89M Sell
6,164
-34
-0.5% -$14.8K 0.06% 321
2024
Q1 		$2.59M Sell
6,198
-2,291
-27% -$968K 0.05% 358
2023
Q4 		$3.45M Buy
8,489
+460
+6% +$170K 0.07% 284
2023
Q3 		$2.9M Buy
8,029
+1,267
+19% +$443K 0.07% 302
2023
Q2 		$2.39M Buy
6,762
+84
+1% +$28.3K 0.05% 367
2023
Q1 		$2.1M Sell
6,678
-2,859
-30% -$857K 0.05% 390
2022
Q4 		$2.75M Buy
9,537
+410
+4% +$125K 0.07% 311
2022
Q3 		$2.64M Buy
9,127
+371
+4% +$107K 0.07% 290
2022
Q2 		$2.47M Sell
8,756
-252
-3% -$67.5K 0.06% 320
2022
Q1 		$2.35M Buy
9,008
+1,267
+16% +$301K 0.05% 361
2021
Q4 		$1.7M Sell
7,741
-210
-3% -$40.8K 0.04% 475
2021
Q3 		$1.44M Buy
7,951
+15
+0.2% +$2.93K 0.03% 493
2021
Q2 		$1.6M Sell
7,936
-1,015
-11% -$212K 0.04% 455
2021
Q1 		$1.92M Sell
8,951
-360
-4% -$79.1K 0.05% 387
2020
Q4 		$2.2M Sell
9,311
-443
-5% -$102K 0.06% 346
2020
Q3 		$2.65M Sell
9,754
-15,207
-61% -$4.2M 0.07% 277
2020
Q2 		$7.25M Buy
24,961
+1,237
+5% +$335K 0.21% 118
2020
Q1 		$5.64M Buy
23,724
+236
+1% +$54.1K 0.2% 131
2019
Q4 		$5.14M Sell
23,488
-3,503
-13% -$709K 0.14% 167
2019
Q3 		$4.57M Buy
26,991
+39
+0.1% +$6.9K 0.13% 182
2019
Q2 		$4.94M Buy
26,952
+464
+2% +$81.1K 0.14% 182
2019
Q1 		$4.87M Sell
26,488
-399
-1% -$73.7K 0.14% 182
2018
Q4 		$4.46M Sell
26,887
-1,391
-5% -$241K 0.14% 180
2018
Q3 		$5.45M Sell
28,278
-1,014
-3% -$181K 0.14% 178
2018
Q2 		$4.98M Sell
29,292
-790
-3% -$122K 0.13% 186
2018
Q1 		$4.9M Sell
30,082
-2,513
-8% -$410K 0.13% 200
2017
Q4 		$4.88M Buy
32,595
+10,135
+45% +$1.5M 0.12% 216
2017
Q3 		$3.42M Buy
+22,460
New +$3.38M 0.09% 272
2016
Q3 		$3.42M Buy
+22,460
New +$2.12M 0.09% 272

Other funds holding VRTX

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
BHIA
Birch Hill Investment Advisors Boston, Massachusetts $2.47B AUM 20.95% 1-Year Est. Return
CTB
Country Trust Bank Bloomington, Illinois $5.71B AUM 25.48% 1-Year Est. Return
CNB
Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return
GIA
Gateway Investment Advisers Cincinnati, Ohio $10.1B AUM 40.26% 1-Year Est. Return
II
IFM Investors Melbourne, Australia $15.1B AUM 40.57% 1-Year Est. Return

Crossmark Global Holdings's VRTX Position: Q2 2026 in Review

Crossmark Global Holdings increased its Vertex Pharmaceuticals (VRTX) stake by 4.6% in Q2 2026, buying an estimated $55K and bringing the position to 2,828 shares worth $1.4M. The position accounts for 0.02% of the portfolio, ranked #549.

Crossmark Global Holdings first reported a position in VRTX in Q3 2016 and has held it in 37 quarters since. The position peaked at $7.25M in Q2 2020. 327 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Crossmark Global Holdings held 2,828 shares of Vertex Pharmaceuticals worth $1.4M as of Q2 2026.
  • Crossmark Global Holdings bought 124 Vertex Pharmaceuticals shares in Q2 2026, an estimated $55K.
  • Vertex Pharmaceuticals made up 0.02% of Crossmark Global Holdings's portfolio in Q2 2026, its #549 holding.
  • Crossmark Global Holdings first reported a position in Vertex Pharmaceuticals in Q3 2016 and has held it in 37 quarters since.
  • Crossmark Global Holdings's Vertex Pharmaceuticals position peaked at $7.25M in Q2 2020.
  • 327 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Crossmark Global Holdings's 13F filing for Q2 2026, filed 16 Jul 2026.